A tale of two worlds in prescribing etidronate for osteoporosis
Author:
- 1 November 1997
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 350 (9088) , 1340
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced OsteoporosisNew England Journal of Medicine, 1997
- The Prevention of Early Postmenopausal Bone Loss by Cyclical Etidronate TherapyThe American Journal of Medicine, 1997
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapyThe American Journal of Medicine, 1993
- Intermittent Cyclical Etidronate Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990